文献速递疼痛医学

冷却射频消融与标准射频消融治疗慢性小关节源性下腰痛的随机非劣效试验

Prospective, non-inferiority, multicenter, randomized, single-blind clinical trial comparing cooled radiofrequency ablation to standard radiofrequency ablation to manage chronic facetogenic lumbar back pain.
PubMed 文献 · Reg Anesth Pain Med · 2026-03-13

这项前瞻性、非劣效、多中心、随机、单盲试验比较冷却射频消融(CRFA)与标准射频消融(SRFA)治疗慢性小关节源性下腰痛。因资金重新分配和严格医保标准提前终止,74例患者随机分组(CRFA 37例,SRFA 37例),61例完成6个月主要终点。两组均显著降低NRS疼痛评分,CRFA满足预设非劣效标准(p=0.0069),6个月时≥50%疼痛缓解率CRFA为74.1%、SRFA为64.7%,两组在6和12个月的功能与生活质量改善相当。

要点

  • CRFA对SRFA在6个月≥50%疼痛缓解率上达到非劣效(p=0.0069)。
  • 两组NRS评分从基线显著下降,各时间点组间无统计学差异。
  • 两组在ODI、SF-36(PF)、EQ-5D-5L和GPE上6和12个月均显著改善。

核心结论

  • 尽管样本量小于预期(因申办方提前终止),在适当患者选择和规范操作技术下,CRFA与SRFA均可缓解慢性小关节源性下腰痛并改善残疾、功能和生活质量达6–12个月。

研究设计与样本

  • 前瞻性、非劣效、多中心、随机、单盲临床试验,纳入经两次阳性内侧支阻滞(MBB)诊断的腰椎小关节源性下腰痛患者,随机接受CRFA或SRFA。
  • 目标入组188例,因资金重新分配和严格医保标准(要求双MBB疼痛缓解≥80%)在18个月后提前终止;74例随机并纳入意向治疗分析(CRFA 37例,SRFA 37例),61例完成6个月主要终点访视(CRFA 27例,SRFA 34例)。
  • 主要终点为6个月时NRS(过去7天疼痛)较基线下降≥50%的受试者比例,随访至12个月。
  • 次要终点包括SF-36生理功能(PF)、Oswestry残疾指数(ODI)、全局感知效应量表(GPE)和EQ-5D-5L指数变化。

主要发现

  • CRFA和SRFA在各时间点均较基线显著降低NRS疼痛评分(p≤0.0001),且达到临床相关改善。
  • CRFA满足相对SRFA的预设非劣效标准(p=0.0069),主要终点≥50%疼痛缓解率CRFA为74.1%、SRFA为64.7%。
  • CRFA从基线的NRS降幅数值上更大(-4.3 vs -3.4),两种治疗均超过最小临床重要差异阈值。
  • 各时间点两组NRS评分无统计学显著差异,可能因研究提前终止(仅入组52%)。
  • 两组在6和12个月的NRS、EQ-5D-5L、ODI、SF-36(PF)和GPE均显示显著且相当的改善。

关键数值与推荐

  • 主要终点:6个月时NRS疼痛评分较基线下降≥50%的受试者比例。
  • 非劣效检验:CRFA相对SRFA满足预设非劣效标准(p=0.0069)。
  • 6个月≥50%疼痛缓解率:CRFA 74.1%,SRFA 64.7%。
  • NRS从基线变化:CRFA -4.3,SRFA -3.4(数值比较,组间无统计学差异)。
  • 两组各时间点NRS较基线改善均p≤0.0001。

临床怎么用

  • 对经两次阳性内侧支阻滞诊断的慢性小关节源性下腰痛患者,CRFA和SRFA均可作为可选射频消融方式。
  • CRFA在6个月疼痛缓解率上不劣于SRFA,临床选择可综合考虑设备条件与操作技术。
  • 治疗后6–12个月可见疼痛、残疾、功能和生活质量的显著改善。

局限性

  • 研究因资金重新分配和严格医保标准提前终止,仅入组目标的52%(74/188),样本量小于预期。
  • 组间NRS差异无统计学显著性可能受提前终止和样本量不足影响。
  • 仅61例(CRFA 27例,SRFA 34例)完成6个月主要终点访视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low back pain is a leading cause of disability. Up to 45% of lumbar spine pain may be facetogenic. Both standard radiofrequency ablation (SRFA) and cooled radiofrequency ablation (CRFA) have been deployed to treat facetogenic pain. METHODS: Patients with lumbar facetogenic back pain, identified by two positive medial branch blocks (MBBs), were randomized to treatment with CRFA or SRFA. The primary endpoint was the proportion of subjects whose back pain decreased by ≥50% on the Numeric Rating Scale (NRS (usual): patient's level of pain over the past 7 days) at 6 months, with subjects followed through 12 months. Secondary endpoints included changes in SF-36 (36-Item Short Form Health Survey) Physical Functioning (PF), Oswestry Disability Index (ODI), Global Perceived Effect scale (GPE), and EQ-5D-5L index (EuroQol's Health-Related Quality of Life Score using 5 levels over 5 dimensions).Enrollment (target 188) ended early after 18 months due to funding reallocation and strict Medicare criterion requiring ≥80% pain relief from dual MBBs. RESULTS: 74 patients (37 CRFA, 37 SRFA) were randomized, treated, and included in the intention-to-treat analysis. 61 patients (27 CRFA, 34 SRFA) completed the 6-month primary endpoint visit. Both CRFA and SRFA provided robust, statistically significant and clinically relevant reductions in NRS pain scores from baseline at every time point (p≤0.0001). CRFA met the predefined non-inferiority criterion relative to SRFA (p=0.0069), with a high proportion of both groups achieving ≥50% pain relief at the primary endpoint-74.1% with CRFA and 64.7% with SRFA. Although CRFA showed numerically greater reductions in NRS pain scores from baseline (-4.3 vs -3.4), both treatments exceeded the minimal clinically important difference threshold. No statistically significant differences in NRS scores were observed between groups at any time point, likely due to the premature termination of the study (only 52% enrolled). Both groups also showed significant and comparable improvements in NRS, EQ-5D-5L, ODI, SF-36 (PF), and GPE at 6 and 12 months. CONCLUSION: Despite the smaller than intended sample size, due to early termination by the sponsor, this study demonstrated that with appropriate patient selection and proper procedural technique, both CRFA and SRFA can relieve chronic facetogenic low back pain, improve disability, function, and quality of life for 6-12 months. TRIAL REGISTRATION NUMBER: NCT04803149.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Provenzano DA, Li S, Deer TA, et al. Prospective, non-inferiority, multicenter, randomized, single-blind clinical trial comparing cooled radiofrequency ablation to standard radiofrequency ablation to manage chronic facetogenic lumbar back pain. Reg Anesth Pain Med. 2026. PMID: 41825940. doi:10.1136/rapm-2025-107299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。